Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Walter Reed Army Medical Center
- Study ID
- NCT00512876
- Status
- Completed
Conditions
- Corneal Neovascularization
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 74 Years
- Healthy Volunteers
- Accepted
Interventions
- Bevacizumab (Avastin) — DRUGBevacizumab 10mg/mL 1 drop BID x 3 weeks
Study Details
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
Key Dates
- First listed
- Aug 8, 2007
- Start date
- Aug 31, 2007
- Status verified
- Jul 2013
- Primary completion
- Jan 31, 2011
- Completion
- Jan 31, 2011
Study Design
- Enrollment
- 24 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Adverse Events (Ocular and Systemic) [ Time Frame: 24 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Walter Reed Army Medical Center | Washington D.C. | District of Columbia | 20307 | - |
Find similar trials in Washington D.C., DC
By research site
Related Studies
- Corneal Crosslinking for Treatment of Corneal NeovascularizationPHASE2/PHASE3 · Recruiting · Price Vision Group · Indianapolis, Indiana